COMP <GO>
INGN vs MRK // REVENUE GROWTH (YOY)
Inogen Inc (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: INGN 3
— MRK 9
▲ REVENUE GROWTH (YOY) LEADER: INGN
LAST: $7.26 (+0.14%) • MKT CAP: $192.7M
revenue-growth
5.90%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
revenue-growth
1.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INGN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INGN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 52.20% | 74.80% | -22.60 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.00% | 20.70% | -47.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.13% | 3.42% | -10.55 | MRK | /fcf-yield <GO> |
| Operating Margin | -10.20% | 34.30% | -44.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | 7.70% | 28.10% | -20.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 5.90% | 1.30% | +4.60 | INGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.46 | 5.19 | -3.73 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.6 | 51.7 | +16.90 | INGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 7.9x | 18.4x | -10.50 | INGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $192.7M | $361.02B | -$360.83B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INGN REV | MRK REV | INGN GROSS % | MRK GROSS % | INGN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $295.3M | $65.01B | 52.2% | 74.8% | -$13.7M | $12.36B |
| FY 2024 | $278.8M | $64.17B | 55.5% | 76.3% | $2.6M | $18.10B |
| FY 2023 | $251.6M | $60.12B | — | — | -$3.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INGN // BETA —
MRK // BETA 0.92